🇪🇺 Voncento in European Union

EMA authorised Voncento on 12 August 2013

Marketing authorisation

EMA — authorised 12 August 2013

  • Application: EMEA/H/C/002493
  • Marketing authorisation holder: CSL Behring GmbH
  • Local brand name: Voncento
  • Indication: Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
  • Status: approved

Read official source →

Voncento in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Voncento approved in European Union?

Yes. EMA authorised it on 12 August 2013.

Who is the marketing authorisation holder for Voncento in European Union?

CSL Behring GmbH holds the EU marketing authorisation.